# Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

> **NCT04862663** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 895 (estimated)

## Conditions studied

- Locally Advanced (Inoperable) or Metastatic Breast Cancer

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Fulvestrant
- **DRUG:** Palbociclib
- **DRUG:** Ribociclib
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04862663
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2027-11-01
- **Final completion:** 2029-08-14
- **Target enrollment:** 895 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862663, "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04862663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*